Mirati Therapeutics Stock News

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mirati's adagrasib may be potentially best-in-class in both CRC and NSCLC.

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in pretreated patients with pancreatic ductal adeno

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.

A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.

Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Ann

Orphazyme A/S and Mirati Therapeutics are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their

Orphazyme A/S (NASDAQ:ORPH) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Volatility and Risk Orphazyme A/S has a beta of 1.46, meaning that its share price is [] The post Head-To-Head Review: Orphazyme A/S (NASDAQ:ORPH) and Mirati Therapeutics (NASDAQ:MRTX) appeared first on ETF Daily News .

Mirati Therapeutics Inc. (NASDAQ:MRTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.45% to the previous days close as strong demand from buyers drove the stock to $144.96. Actively observing the price movement in the last trading, the stock closed the session at $136.18, falling within a range of $131.07 A Bullish 2021 Outlook For Mirati Therapeutics Inc. (NASDAQ: MRTX) Shares Read More »

Related Stocks: UBER , BAX , GPN , APTV , CHNG , DD , WLTW , EHC , CCCS , OGN , MRTX , VIAC , DXC , ANTM , BHVN , FB , HCA , WBA , AMZN , IQV , MDT , BABA , DGNR ,

Related Stocks: SAH , BLMN , FSS , NOG , FRPT , SPNE , ZUO , OLLI , RCII , RDFN , MRTX , LAD , CLDR , PLUG , RUN ,